DIRS.INFO The most relevant business & tech news

☆ P&G flexes its pricing power again in its latest quarter. Wall Street rewards the stock
▼ + stars: | 2023-10-18 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +9 min

P & G's results Wednesday demonstrate that its recent outperformance compared with its staples peers is justified. Quarterly commentary Procter & Gamble delivered on key metrics such as gross margins and organic sales growth. Secondly, excluding declines in China, P & G's volume was up in the rest of the world. Consumers in Western Europe remain relatively resilient, Schulten said, while describing P & G's business in Latin America as "on fire." P & G paid out $2.3 billion in dividends in its fiscal first quarter while repurchasing $1.5 billion worth of common stock.

Persons: Gamble, —, we're, That's, Andre Schulten, it's, Schulten, Jim Cramer's, Jim Cramer, Jim, Joe Raedle Organizations: Procter, Gamble, Wednesday, Dow, Treasury, Walmart, Club, Costco Wholesale, Bunge Limited, Revenue, U.S, Wall, CNBC, Procter & Gamble, Getty Locations: China, U.S, Cincinnati, Western Europe, Latin America, Miami , Florida

☆ Abbott profit beats on strong sales of medical devices, diagnostics
▼ + stars: | 2023-10-18 | by ( ) www.reuters.com time to read: +1 min

Abbott Laboratories logo is displayed on a screen at the New York Stock Exchange (NYSE) in New York City, U.S., October 18, 2021. REUTERS/Brendan McDermid/File Photo Acquire Licensing RightsOct 18 (Reuters) - Abbott Laboratories (ABT.N) on Wednesday tightened its profit forecast for the year after beating estimates for third-quarter earnings on strong demand for its medical devices and diagnostics products. The company is seeing a recovery in sales of its medical devices such as heart valve devices and pacemakers as more older people opt for surgeries that were put off due to the pandemic. Abbott posted a near 17% rise in quarterly sales of its medical devices to $4.25 billion, beating analysts' estimates of $4.16 billion. Excluding items, Abbott earned $1.14 per share, above analysts' estimates of $1.10 per share, according to LSEG data.

Persons: Brendan McDermid, Abbott, Nordisk's Ozempic, Eli Lilly's, Mounjaro, Pratik Jain, Leroy Leo, Anil D'Silva Organizations: Abbott, New York Stock Exchange, REUTERS, Abbott Laboratories, Libre, Nordisk's, Thomson Locations: New York City, U.S, Bengaluru

☆ Our top 5 stocks of October so far as Wall Street rebounds from a September slump
▼ + stars: | 2023-10-17 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +6 min

After a rough September, October has so far been much more kind to stocks and has helped Wall Street cut into some of its third-quarter losses . FL mountain 2023-09-29 Foot Locker's stock performance so far in October. LLY mountain 2023-09-29 Eli Lilly's stock performance so far in October. PANW mountain 2023-09-29 Palo Alto's stock performance so far in October. HUM mountain 2023-09-29 Humana's stock performance so far in October.

Persons: Dow, Locker, Foot, Jim Cramer, Eli Lilly's, Eli Lilly, Jim Cramer's, Jim, Angela Weiss Organizations: Dow Jones, Nasdaq, Nike, Novo Nordisk, Palo Alto Networks, Nvidia, Johnson Controls, Palo Alto, Coterra Energy, Exxon Mobil, Club, Natural Resources, Humana, UnitedHealth, CNBC, New York Stock Exchange, Wall, AFP, Getty Locations: Alto, Israel, U.S, New York City

☆ When is it OK to violate your cost basis to buy more shares of a company?
▼ + stars: | 2023-10-15 | by ( Zev Fima | ) www.cnbc.com time to read: +4 min

This week's question: The cardinal rule of discipline is to not violate cost basis and show patience to buy more high-quality stocks on pullback. How do you evaluate a flying stock which might not come back to levels of cost basis to add more? Since we are not anticipating the stock breaking below our cost basis — it is rallying — we need another way to determine when to buy more shares. If you can't buy below you price basis, you should buy at or below your valuation basis. And then set up points to buy when the valuation goes lower, just as you would when the stock price falls.

Persons: Jim Cramer, Eli Lilly, Ravi, —, Jim Cramer's, Jim, Jensen Huang, Walid Berrazeg Organizations: Nvidia, workloads, Jim Cramer's Charitable, CNBC, Getty Locations: Taipei

[1/2] A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Illustration/File Photo Acquire Licensing RightsOct 12 (Reuters) - Novo Nordisk (NOVOb.CO) warned on Thursday of a surge in counterfeit versions of its weight-loss drug Wegovy and diabetes drug Ozempic offered online, as German authorities gave more details of complex European trades in a fake drug case. "Novo Nordisk has seen a significant increase in illegal online sales," the company said in a statement, referring to products that contain the active ingredient semaglutide. The warning came after Germany's federal drug regulator on Wednesday urged pharmacies and drug distributors to be vigilant following the discovery of wholesale batches of fake Ozempic. The FDA has warned patients to refrain from using a compounded drug if an approved drug is available.

Persons: Victoria Klesty, Ozempic, Novo, Danish drugmaker, Eli Lilly, Lilly, Maggie Fick, Ludwig Burger, Jan Harvey, Susan Fenton Organizations: REUTERS, Novo Nordisk, Nordisk, Prosecutors, U.S . Food, Drug Administration, U.S, FDA, Thomson Locations: Oslo, Norway, Victoria, Loerrach, Swiss, Basel, British, Austria, Germany, Europe, Danish, U.S, United States, Britain

☆ Monthly Meeting Q&A with Jim Cramer on everything from tech to health care to industrials
▼ + stars: | 2023-10-12 | by ( Paulina Likos | ) www.cnbc.com time to read: +13 min

(Todd) Jim Cramer: I believe that the rally in oil was a short squeeze that is now over. (John) Jim Cramer: FTC chair Lina Khan does not have a strong antitrust case against Amazon (AMZN) – her arguments don't make sense. (Norman) Jim Cramer: We like to have something related to the housing cycle that could make money. (James) Jim Cramer: This is more of an art, not a science. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Persons: Jim Cramer's, Jeff Marks, Jim Cramer, It's, Todd, Joe Biden, Tom Jorden, Donald, John, it's, Zev Fima, I've, Peter, Marc Benioff, Lina Khan, Khan, David, Rich Galanti, Eli Lilly, LLY, we've, Lilly, clobbered, Mounjaro, Stanley Black, Decker, that's, James, Michael Steinhardt, Rhonda, Vimal Kapur, Darius Adamczyk, Jim Organizations: Investing Club, Federal Reserve, Nvidia, Fed, Apple, Shark, ESPN, Our, Nasdaq, Amazon, Costco, Diabetes, Procter & Gamble, Honeywell, Electric, GE, Raytheon Technologies, CNBC Locations: Russia, China

How GLP-1 drugs work Sorting through the facts reveals some likely winners and losers. LLY YTD mountain Eli Lilly shares year to date performance It is still early days for GLP-1 medications. Many have seen the rise of GLP-1 drugs as a threat to the medical device industry. Also, not all patients are able to tolerate GLP-1 drugs, which can cause side effects such as nausea. Among other medtech stocks, Plovanic sees GLP-1 drugs as an "incremental positive" for Dexcom, which makes continuous glucose monitors (CGMs), but an "incremental negative" for insulin pump makers like Insulet.

Persons: Insulet, Medtronic, Dexcom, BAX, NASH, Eli Lilly, Peter Verdult, Lilly, Eli Lilly aren't, Piper Sandler, Wegovy, Yasmeen Rahimi, Robbie Marcus, Marcus, hasn't, Baxter, David Low doesn't, William Plovanic, Craig Wong, Pan, Plovanic, Matt O'Brien, O'Brien, Rippling, Simeon Gutman, Morgan Stanley, Gutman, — CNBC's Michael Bloom Organizations: Novo Nordisk, Baxter International, Baxter, GLP, Citi, Novo, Bank of America, Viking Therapeutics, Pharmaceuticals, Pfizer, Amgen, Companies, Fisher, Reuters, Inspire, Systems, JPMorgan, RBC Capital, Walmart, underperformance Locations: GLP, U.S, DaVita, ResMed

Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., September 11, 2023. U.S. producer prices increased more than expected in September amid higher costs for energy products, but underlying inflation pressures at the factory gate continued to moderate. Yield on the benchmark 10-year notes fell to a roughly two-week low as prices rose on safe-haven flows due to fighting in the Middle East that has persisted for a fifth straight day. Advancing issues outnumbered decliners for a 1.51-to-1 ratio on the NYSE, while declining issues outnumbered advancers for a 1.10-to-1 ratio on the Nasdaq. The S&P index recorded 11 new 52-week highs and seven new lows, while the Nasdaq recorded 38 new highs and 124 new lows.

Persons: Brendan McDermid, Fed's Bowman, Raphael Olszyna, J Safra, Michelle Bowman, Christopher Waller, Birkenstock, Tim Wentworth, Drugmaker Eli Lilly, LLY.N, Novo, decliners, advancers, Shashwat Chauhan, Ankika Biswas, Arun Koyyur, Shounak Organizations: New York Stock Exchange, REUTERS, Fed's Bowman Exxon, Nasdaq, Treasury, Federal, Apple, Microsoft, Nvidia, Fed, Energy, Exxon Mobil, Natural Resources, Dow Jones, Walgreens Boots Alliance, Novo Nordisk's, Baxter International, NYSE, Thomson Locations: New York City, U.S, Middle East, Israel, Gaza, Bengaluru

☆ Why investors should buy these fixer-upper names, while sticking with 3 that are set to soar
▼ + stars: | 2023-10-11 | by ( Morgan Chittum | ) www.cnbc.com time to read: +6 min

Oracle Oracle (ORCL) stock has been sliding for some time, with shares down 14% over the past month, even as the stock has climbed more than 33% this year. He added that this is a great level at which to buy Oracle stock. And here are three Club names that need no work, and are well-positioned to soar: Caterpillar Caterpillar (CAT) has weathered the market's volatility well. TJX Companies This is TJX Companies ' (TJX) time to shine, as the off-price retailer has the best business model to capture the spending of a cash-strapped consumer. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Persons: Jim Cramer, Walt Disney, Jim, Disney's, Nelson Peltz, Laxman Narasimhan, There's, Larry, Ellison, it's, we're, TJX, Eli Lilly Eli Lilly, Mounjaro —, Jim Cramer's, Angela Weiss Organizations: Nasdaq, Treasury, Club, Disney, Walt, ESPN, Comcast, Hulu, CNBC, Starbucks, U.S, Oracle Oracle, Oracle, Caterpillar Caterpillar, Caterpillar, Traders, New York Stock Exchange, AFP, Getty Locations: NBCUniversal, China, U.S, Maxx, New York City

☆ Blood tests needed for widespread Alzheimer's diagnosis on the way
▼ + stars: | 2023-10-11 | by ( Deena Beasley | ) www.reuters.com time to read: +6 min

Several Alzheimer's blood tests are in the works – and one is already being sold to consumers – but none have been established as accurate, formally approved by regulators or reimbursed by insurers. Researchers have been working for years on blood tests for Alzheimer's that can replicate these diagnostic tools. The need for blood tests has become more pressing since the FDA approved Leqembi in July. Accurate blood tests are expected to help identify which dementia patients actually have Alzheimer’s, the most common but not the only cause of dementia. "When there are widely available, scalable, sensitive and specific blood tests it will be an absolute game changer for Alzheimer's patients."

Persons: Denis Balibouse, Eli Lilly, Dr, Sarah Kremen, Eliezer Masliah, Eisai, Michael Irizarry, Roche, Bruce Jordan, Russ Paulsen, Deena Beasley, Caroline Humer, Bill Berkrot Organizations: Memory Centre, of Readaptation, University Hospital, REUTERS, FDA, Sinai Medical Center, Wednesday, Quest Diagnostics, National Institute, Aging, U.S . National Institutes of Health, C2N Diagnostics, Roche Diagnostics, Alzheimer's Association, RAND, Thomson Locations: Geneva, Switzerland, Leqembi, Eisai, Los Angeles, U.S

☆ Shares of dialysis providers drop after Ozempic's early kidney trial success
▼ + stars: | 2023-10-11 | by ( ) www.reuters.com time to read: +2 min

The outdoor sign seen at the DaVita Dialysis clinic in Denver February 16, 2016. U.S.-listed shares of Fresenius fell 16.4%, to $17.5, and Davita fell about 16%, to $76.7, in premarket hours. Shares of U.S.-based Baxter International (BAX.N), which makes products used by dialysis therapy providers, also fell about 9%, to $33.99 premarket. Davita and U.S.-listed shares of Fresenius Medical are among the top percentage losers on the New York Stock Exchange. As of Tuesday's close, U.S.-listed shares of Fresenius were up about 28.2%, Davita's shares were up 22.2%, while Baxter's shares were down about 27% so far this year.

Persons: Rick Wilking, Ozempic, Danish drugmaker, Veronika Dubajova, Davita, Eli Lilly's, Akash Tewari, Fresenius, Mariam Sunny, Janane Venkatraman, Pooja Desai Organizations: REUTERS, Novo Nordisk's, Citi, Baxter, Jefferies, Fresenius, New York Stock Exchange ., Thomson Locations: Denver, Danish, Fresenius, New York Stock Exchange . Frankfurt, U.S, Bengaluru

Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., September 11, 2023. ET is expected to show the producer price index for final demand increased 0.3% last month after a 0.7% rise in August, ahead of Thursday's closely watched consumer inflation data. Yields on government bonds have eased from their multi-year highs on dovish remarks from Fed officials earlier this week. Central bank officials such as Fed Governor Christopher Waller, Atlanta Fed President Raphael Bostic and Boston Fed President Susan Collins are also scheduled to speak on Wednesday. Exxon Mobil (XOM.N) lost 1.7% as the oil and gas producer is set to buy shale producer Pioneer Natural Resources (PXD.N) in an all-stock deal valued at $59.5 billion.

Persons: Brendan McDermid, Fed's Bowman, Michelle Bowman, Christopher Waller, Raphael Bostic, Susan Collins, Mark Haefele, Birkenstock, Tim Wentworth, Piper Sandler, Drugmaker Eli Lilly, LLY.N, Novo, Shashwat Chauhan, Ankika Biswas, Arun Koyyur, Shounak Organizations: New York Stock Exchange, REUTERS, Companies, Fed's Bowman Exxon, Futures, Dow, Nasdaq, Treasury, Federal, Labor Department, Atlanta Fed, Boston Fed, UBS Global Wealth Management, Traders, Microsoft, Nvidia, Palestinian, Hamas, Dow e, Walgreens Boots Alliance, Arista Networks, Exxon Mobil, Natural Resources, Novo Nordisk's, Baxter International, Thomson Locations: New York City, U.S, Gaza, Thursday's, Middle East, Israel, Bengaluru

☆ Here's a rapid-fire update on all 36 stocks in our portfolio, including our latest addition
▼ + stars: | 2023-10-11 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +16 min

Here's a rapid-fire update on all stocks in Jim Cramer's Charitable Trust, the portfolio we use for the CNBC Investing Club. After reducing expenses to improve margins on its retail business, Jim said it's on the right track. Costco Wholesale (COST): Costco remains one of Jim's favorite stocks in the entire our entire portfolio. Ford Motor (F): Jim expressed confidence in Ford CEO Jim Farley, as the targeted United Auto Workers strike approaches the one-month mark. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Jim Cramer's, Jim, there's, it's, Bausch, we're, We've, Coterra, Dupont, We're, Nelson Peltz, Peltz, Estee Lauder, Patience, Fabrizio Freda, Emerson, Jim Farley, Ford, Locker, Mary Dillon, GEHC, Vimal Kapur, Bruce Broussard, Broussard, he's, Eli Lilly, Lilly, Mark Zuckerberg, Morgan Stanley, Morgan Stanley's, James Gorman, Laxman Narasimhan, Elliott, Stanley Black, Decker, Piper, Wells Fargo, Wells, Jim Cramer, Jim Cramer Rob Kim Organizations: Jim Cramer's Charitable Trust, CNBC, Club, Apple, Federal Trade, Broadcom, VMWare, Bausch Health, Caterpillar, Costco Wholesale, Costco, Coterra Energy, Exxon Mobil, Natural Resources, Disney, ESPN, Hulu, Comcast, Emerson, National Instruments, Ford, United Auto Workers, Nike, GE Healthcare, Electric, GE, Honeywell International, Honeywell, Humana, Linde, LIN, Microsoft, Nvidia, Oracle, Alto Networks, cyberattacks, Palo Alto Networks, Procter & Gamble, Pioneer, Exxon, Constellation Brands, Elliott Management, FactSet, TJX, Marshalls, Wynn Resorts, WYNN, Jim Cramer's Charitable Locations: China, U.S, Maxx, Las Vegas, Boston, Macau, Asia

☆ 15 stocks with a history of dividend growth are expected to deliver once again this year
▼ + stars: | 2023-10-10 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +5 min

Broadcom (AVGO), Caterpillar (CAT) and Eli Lilly (LLY) are among the 15 Club stocks with a streak of annual dividend growth that Wall Street expects to continue in their current fiscal years. Long-term investors should look to own companies with a history of dividend growth instead of chasing stocks with high yields, Morgan Stanley strategists said in a note to clients this week. However, Morgan Stanley's note made us curious to screen our portfolio for stocks with strong dividend growth track records that are expected to persist. To help us project which stocks will keep their dividend growth streaks alive, we also examined analyst estimates for total per-share payouts in their current fiscal year. Bottom line In any case, dividend growth over time is certainly welcome and can help increase total investment return, assuming the distributions are reinvested instead of taking cash.

Persons: Eli Lilly, Morgan Stanley, Jim Cramer, —, Jim, Morgan Stanley's, Stanley Black, Decker, Eli Lilly Honeywell, we're, Gamble, Jim Cramer's, Spencer Platt Organizations: Broadcom, Caterpillar, Trust, Club, Companies, Natural Resources, Procter, Gamble, Emerson Electric, Apple, Broadcom Costco Wholesale, LIN, Microsoft, Oracle, CNBC, New York Stock Exchange, Getty

☆ Pepsi has long way to go to win Ozempic challenge
▼ + stars: | 2023-10-10 | by ( Anita Ramaswamy | ) www.reuters.com time to read: +3 min

The purveyor of Gatorade and Cheetos boosted operating profit 14%, to about $4 billion, after hiking prices by at least 10% for the seventh consecutive quarter. The quantity of drinks and snacks sold is slumping, however, and anti-obesity drugs are just starting to make their mark. Pepsi’s shares have tumbled 14% since May, lagging the 5% gain in the S&P 500 Index (.SPX) over the same period. The head of Walmart’s (WMT.N) U.S. drugstores told Bloomberg that customers taking Ozempic, Wegovy and others are pulling back on junk-food purchases. The latest results from Pepsi quelled fears of any immediate impact, but also raise questions about the future.

Persons: Brendan McDermid, Eli Lilly, drugstores, Morgan Stanley, Boss Ramon Laguarta, Laguarta, Lay, Hugh Johnston, Jeffrey Goldfarb, Sharon Lam Organizations: REUTERS, Reuters, PepsiCo, Gatorade, Novo Nordisk, Bloomberg, Pepsi, Frito, Thomson Locations: New York City, U.S, Wegovy

☆ Down syndrome families' fight for access to Alzheimer’s trials, treatments
▼ + stars: | 2023-10-10 | by ( Julie Steenhuysen | ) www.reuters.com time to read: +9 min

In an extended portion of Eisai’s main Leqembi trial, CAA was associated with one death. 'THE DIGNITY OF RISK'Hillerstrom said the groups are "very strongly" lobbying Eisai and Lilly to conduct the safety trials in Down syndrome, and said he has been meeting with the companies to push them to design such trials. Lilly declined to comment on whether it is considering either a safety trial or taking part in that study. An Eisai spokeswoman said the company "has no immediate plans" to conduct clinical trials of Leqembi in people with Down syndrome. The company is collaborating with LuMind in a study gathering data on how Alzheimer's manifests in people with Down syndrome.

Persons: Oskar Hillerstrom, Lianor, Hampus, Brian Snyder, Lianor da Cunha, Oskar, de Oeiras, Teresa, Oskar’s, Hampus Hillerstrom, Eli Lilly's, LuMind, Hillerstrom, Lilly, Emily Largent, Beau Ances, Louis, I've, Ances, I'm, Michael Rafii, William Mobley, Mobley, Dawn Brooks, donanemab, Margot Rhondeau, Hannah, Julie Steenhuysen, Caroline Humer, Bill Berkrot Organizations: REUTERS, Rights, Reuters, CAA, University of Pennsylvania Perelman School of Medicine, Medicare, U.S . Food, Drug Administration, Washington University, National Institute, Aging, University of Southern, UC San Diego School of Medicine, LuMind, Syndrome, Thomson Locations: Lexington , Massachusetts, U.S, Santo, Portugal, United States, St, University of Southern California

☆ What are global firms with presence in Israel doing after Hamas attack
▼ + stars: | 2023-10-09 | by ( ) www.reuters.com time to read: +4 min

Following are the steps taken by the companies ranging from airlines to banks:TRAVELSeveral Asian, European and U.S. airlines have suspended direct flights to Tel Aviv. Delta Air Lines (DAL.N):The airline said it continues to monitor events in the region and has made the decision to cancel Delta-operated Tel Aviv flights through Oct. 31. Goldman Sachs (GS.N):The bank's employees at its office in Tel Aviv have been asked to work from home, a spokesperson said. TECHNvidia (NVDA.O):The world's largest maker of chips used for artificial intelligence and computer graphics said it had canceled an AI summit scheduled for Tel Aviv next week. CONSUMER AND RETAILH&M (HMb.ST):The clothing company said its local franchise partner has temporarily closed all stores in Israel.

Persons: Amir Cohen, El, Goldman Sachs, Morgan Stanley, Gautam Adani's, Jensen Huang, PHARMA Eli Lilly, Lilly, Priyamvada C, Mehr Bedi, Ananya Mariam Rajesh, Khushi, Jaiveer Singh, Samrhitha, Helen Reid, Sriraj Kalluvila, Shounak Dasgupta, Shinjini Organizations: Gaza, REUTERS, Palestinian, Hamas, Tel Aviv . Delta Air Lines, Royal, Chevron, JPMorgan Chase, Reuters, Bank of America, Bloomberg News, FedEx, TECH Nvidia, Tel, Inditex SA, PHARMA, Thomson Locations: Sderot, Israel, U.S, Tel Aviv, Royal Caribbean, Haifa Port, Zara, Bengaluru, London

☆ Weight-loss drugs fuel boom for firms that fill syringes
▼ + stars: | 2023-10-09 | by ( Maggie Fick | ) www.reuters.com time to read: +6 min

[1/5] Catalent's automated visual inspection systems that check every pre-filled syringe to ensure product integrity are seen, in Brussels, Belgium, 2023. Eli Lilly's (LLY.N) Mounjaro is expected to be approved for weight-loss in the United States this year. The U.S. Inflation Reduction Act is also boosting development of biologic drugs, some of which are injected. Injectables are increasingly used in elderly care settings, and some new Alzheimer's and generic arthritis drugs are administered by injection. One healthcare investor said CDMOs' ability to boost capacity will determine how fast the obesity drug market grows.

Persons: Wegovy, it's, Savant, Morgan Stanley, Eli Lilly's, Mounjaro, Chris Chen, Cornell Stamoran, Fujifilm Diosynth, Germany's Vetter, Lilly, Marc Casper, CDMOs, Luke Sergott, Catalent, Catalent's Stamoran, Maggie Fick, Patrick Wingrove, Josephine Mason, Catherine Evans Organizations: REUTERS Acquire, Pfizer, HK, Fujifilm, Fujifilm Corp, Novo, Reuters, Research, Insight Partners, Barclays, Thomson Locations: Brussels, Belgium, Handout, United States, WuXi, Europe, GLP, Anagni, Italy, Bloomington , Indiana, U.S, New York

☆ U.S. employers covering weight-loss drugs could nearly double in 2024 - survey
▼ + stars: | 2023-10-09 | by ( ) www.reuters.com time to read: +2 min

A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, August31, 2023. The survey of 502 employers by Accolade (ACCD.O), a company that provides healthcare programs for employers, and research firm Savanta said 43% of the employers it polled could cover GLP-1 drugs in 2024 compared to 25% that cover them now. Nearly all the companies that are covering GLP-1 drugs plan to keep covering them next year, according to the survey. Employers that cover weight-loss drugs are facing a spike in their healthcare costs because of the growing popularity of Wegovy. Benefits consultant Aon (AON.N) said 1 percentage point of the 8.5% increase in employer healthcare costs it predicted for next year would be driven by employee take-up of weight-loss drugs.

Persons: Victoria Klesty, Savanta, James Wantuck, Ozempic, Eli Lilly's, Leroy Leo, Shinjini Organizations: REUTERS, Novo Nordisk, Accolade, Employers, Novo, Novo Nordisk's Wegovy, Thomson Locations: Oslo, Norway, August31, Victoria, Novo, Novo Nordisk's, United States, Bengaluru

☆ Cramer says Vertex has a drug that may address the 'largest market opportunity in the world'
▼ + stars: | 2023-10-09 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +1 min

CNBC's Jim Cramer on Monday suggested that investors keep an eye on Vertex Pharmaceuticals (VRTX), a biotechnology company developing a drug to treat acute pain that is not an opioid. They have a plan — Vertex," Cramer said on "Squawk on the Street." Vertex — which makes most of its revenue from cystic fibrosis treatment Trikafta — has late-stage trials underway for the pain drug, known as VX-548. "I do believe that if they have something, it would be the largest market opportunity in the world," Cramer said, adding that late-stage study results for VX-548 are expected "within the year." The firm, which has a buy-equivalent rating on Vertex shares, said it sees similarities between the current pain market and the obesity market one to two years ago.

Persons: CNBC's Jim Cramer, Cramer, —, Jim Cramer's, Eli Lilly, Mounjaro, Lilly Organizations: Vertex Pharmaceuticals, VX, Leerink Partners, Charitable Trust, CNBC, Club, U.S

☆ Cramer says investors should stick with oil firm Pioneer amid acquisition report
▼ + stars: | 2023-10-06 | by ( Jeff Marks | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a Morning Meeting livestream at 10:20 a.m. But Jim Cramer said selling stocks on an economy that's putting many people to work, with little wage inflation, makes no sense. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Jim, Scott Sheffield's, Eli Lilly, BofA, Lilly's, Jim Cramer's Organizations: CNBC, Labor Department, Federal Reserve, Street, Exxon Mobil, Natural Resources, Eli Lilly Bank of America Locations: U.S

☆ Here are Friday's biggest analyst calls: Netflix, Nvidia, Eli Lilly, Disney, Levi's, Exxon, Walmart and more
▼ + stars: | 2023-10-06 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

JPMorgan reiterates Exxon as overweight JPMorgan said it's standing by its buy rating on the oil and gas giant. Seaport initiates Netflix as buy Seaport said it sees plenty of upside in shares of Netflix. JPMorgan upgrades Eaton to overweight from neutral JPMorgan said the industrial and electrical company is best in class. UBS reiterates Levi's as buy UBS said Levi's is still an attractive stock despite the company's disappointing earnings report Thursday. " JPMorgan upgrades Apellis to overweight from neutral JPMorgan said the pharmaceutical company is well-positioned for more upside.

Persons: Piper Sandler, Bernstein, Disney, XOM, Jefferies, TD Cowen, Cowen, Eaton, Eli Lilly, Doug McMillon, Berenberg, Morgan Stanley, Meta, Levi's, Oppenheimer downgrades O'Reilly, AutoZone, Oppenheimer, it's, Truist Organizations: Disney, Netflix, Hulu, JPMorgan, Exxon, Barclays, Nvidia, Intel, Gaudi, Citi, Discover Citi, DFS, Seaport, Bank of America, Energy, of America, Apple, Vegas, Prix, Clearway Energy, Walmart, United Auto Workers, Auto, Meta, UBS Locations: Parks, NVDA, China, ETN, TEL, AZO, ORLY

☆ Eli Lilly is on a buying spree. Here’s what it means for investors like us
▼ + stars: | 2023-10-05 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +9 min

Still, he said it's "healthy" for a company like Eli Lilly — valued over $500 billion, as of Thursday — to be executing smaller deals. "They can still put their mark on an asset or a constellation of drugs," said Seigerman, who has a buy rating and $633-per-share price target on Eli Lilly stock. LLY 1Y mountain Eli Lilly's stock performance over the past 12 months. Details on the deals The three companies Eli Lilly bought this summer have drugs in various stages of the clinical development process. In the near term, though, they may result in a noisy third-quarter earnings report as Eli Lilly records the acquisitions.

Persons: Eli Lilly, Mounjaro, Jim Cramer, Eli Lilly's, Lilly, –, Verzenio, Evan Seigerman, Eli Lilly —, Seigerman, Lilly's, Dice, Versanis, Sigilon, that's, BMO's Seigerman, Eli, we'd, Jim Cramer's, Jim, Daniel Acker Organizations: Indianapolis, U.S . Food, Drug Administration, BMO Capital, Immunology, Therapeutics, Siligon Therapeutics, Oncology, Club, Department of Health, Human Services, Dice Therapeutics, Alzheimer's, Treasury, CNBC, Bloomberg, Getty

Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., September 26, 2023. While the 30-year Treasury yield crossed above 5% for the first time since August 2007, the 10-year and five-year yields hit their highest since 2007. The CBOE volatility index (.VIX), Wall Street's "fear gauge", briefly hit a five-month high and topped its long-term average of 20. A day after U.S. job openings unexpectedly rose in August, investors will closely monitor September ADP National Employment data at 8:15 a.m. Reporting by Ankika Biswas and Shashwat Chauhan in Bengaluru; Editing by Shounak DasguptaOur Standards: The Thomson Reuters Trust Principles.

Persons: Brendan McDermid, Kevin McCarthy, Mark Haefele, Haefele, Austan Goolsbee, Michelle Bowman, Eli Lilly, LLY.N, Mike Mason, Ankika Biswas, Shashwat Chauhan, Shounak Dasgupta Organizations: New York Stock Exchange, REUTERS, Apple, U.S . House Republicans, Treasury, Microsoft, Nvidia, Dow e, Nasdaq, Federal, UBS Global Wealth, Institute, Supply, PMI, Chicago, Traders, Dow, Intel, Thomson Locations: New York City, U.S, Bengaluru

Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., September 28, 2023. Consumer discretionary (.SPLRCD) led declines in the major S&P 500 sectors, falling 2.2%, while beaten-down utilities (.SPLRCU) dropped 1.8%. Declining issues outnumbered advancers by a 4.74-to-1 ratio on the NYSE and by a 3.17-to-1 ratio on the Nasdaq. The S&P index recorded one new 52-week high and 48 new lows, while the Nasdaq recorded 11 new highs and 225 new lows. Reporting by Ankika Biswas and Shashwat Chauhan in Bengaluru Editing by Vinay DwivediOur Standards: The Thomson Reuters Trust Principles.

Persons: Brendan McDermid, Eli Lilly, we're, David Russell, Raphael Bostic, Keybanc, McCormick, Ankika Biswas, Shashwat Chauhan, Vinay Dwivedi Organizations: New York Stock Exchange, REUTERS, Dow, Nasdaq, Apple, Microsoft, Artificial Intelligence, Treasury, Boeing, Reuters, United Airlines, Labor Department, Investor, ADP, Atlanta Fed, Fed, Dow Jones, HP, BofA Global Research, Biopharma, NYSE, Thomson Locations: New York City, U.S, Bengaluru

Search resuls for: "LLY"

25 mentions found